The estimated Net Worth of David Charles Lubner is at least $3.59 Миллион dollars as of 14 August 2015. David Lubner owns over 9,500 units of Dyne Therapeutics stock worth over $2,567,902 and over the last 12 years David sold DYN stock worth over $1,018,920.
David has made over 10 trades of the Dyne Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently David exercised 9,500 units of DYN stock worth $75,430 on 14 August 2015.
The largest trade David's ever made was exercising 88,391 units of Dyne Therapeutics stock on 7 February 2014 worth over $139,658. On average, David trades about 6,572 units every 20 days since 2013. As of 14 August 2015 David still owns at least 78,770 units of Dyne Therapeutics stock.
You can see the complete history of David Lubner stock trades at the bottom of the page.
David's mailing address filed with the SEC is 1560 TRAPELO ROAD, , WALTHAM, MA, 02451.
Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes и Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..
Dyne Therapeutics executives and other stock owners filed with the SEC include: